is presently being evaluated clinically as a preventive agent in women at high risk of developing the disease (4-6). The 4 To whom correspondence should be addressed molecular mechanisms through which estrogens contribute to We have examined the ability of 17β-estradiol (E2) to development of breast cancers in humans are not presently induce development of mammary cancers in the female defined.
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ACI rat. Continuous treatment with E2, delivered through
The ACI rat strain is an inbred line derived from a cross release from s.c. Silastic tubing implants containing 27.5 mg between the August and Copenhagen strains (7). The ACI crystalline hormone, resulted in rapid development of strain differs from nearly all other inbred rat strains in that palpable mammary tumors in ovary-intact ACI rats. In a ACI rats develop mammary cancers at high incidence when population of 21 E2-treated rats, palpable tumors were treated with the synthetic estrogen diethylstilbestrol (DES*).
first observed following 99 days treatment and 100% of
The propensity of the ACI rat to develop mammary carcinoma the treated population developed tumors within 197 days.
in response to DES treatment was first noted by Dunning et al.
The median and mean times to appearance of first palpable
in 1947 (8) and has been confirmed in several studies, not all tumor were 143 and 145 days respectively. All mammary of which are cited herein (9-19). Whereas ACI rats develop tumors were classified as carcinomas and invasive features mammary cancers when chronically treated with certain estrowere observed. Circulating E2 levels in the treated animals gens, spontaneous mammary cancers are rare in this strain at the time of sacrifice averaged 185 pg/ml serum. Mam- (8, (14) (15) (16) 20, 21) . Similarly, ACI rats develop relatively few mary tumors were not observed in ovary-intact female mammary cancers when treated with chemical carcinogens, ACI rats that were not treated with E2. This is the first such as dimethylbenz [a] anthracene (DMBA), N-methylnitrosoreport indicating that this naturally occurring estrogen is urea (MNU) (22, 23) or ionizing radiation (13,16). Because of capable of inducing mammary cancers in the ACI rat strain.
the potential importance of the ACI rat strain as an animal Mammary carcinoma did not develop in a population of model for examining the role of estrogens in the etiology of 11 ovariectomized female ACI rats treated with E2 for a human breast cancers, we have examined the ability of the period of 140 days. Circulating E2 levels in the treated naturally occurring estrogen 17β-estradiol (E2) to induce ovariectomized animals averaged 207 pg/ml. These data development of mammary cancers in ovary-intact and ovariindicate that the ovary modulates estrogen-mediated mamectomized ACI rats. Our data indicate that E2 rapidly induces mary carcinogenesis in this rat strain. Both ovary-intact development of mammary carcinomas that often display and ovariectomized female ACI rats displayed similar invasive characteristics and that the ovary modulates mammary susceptibilities to E2-induced pituitary tumors and hypercarcinoma development in animals chronically treated with E2. prolactinemia. Pituitary weight was increased 6.0-fold in ovary-intact ACI rats and 5.3-fold in ovariectomized female Materials and methods rats. Circulating prolactin levels averaged 2318 ng/ml in Introduction University of Nebraska Medical Center. Ovary-intact animals were allowed continuous access to a standard laboratory chow diet (Harlan Teklad, Madison, Numerous epidemiological studies indicate the importance of WI). Treatment of intact females (n ϭ 21) with E2 was initiated when the estrogens in the etiology of human breast cancer (1, 2) . Both animals were 61-63 days of age. A population of three untreated ovary-intact early onset of menarche and late onset of menopause are females served as controls. Numerous published studies indicate that ovaryassociated with increased risk of developing breast cancer. It intact ACI rats very rarely develop mammary cancers spontaneously (8, (14) (15) (16) 20, 21) . In a second experiment, female rats were ovariectomized at 26 is generally believed that this increased risk results from days of age and obtained from the vendor at 32 days of age. Upon arrival at prolonged exposure of the mammary tissues to the estrogens our facility, these animals were fed a semi-purified diet formulated in accordance with guidelines of the American Institute of Nutrition (24) . E2 treatment of the ovariectomized animals (n ϭ 11) was initiated when the *Abbreviations: DES, diethylstilbestrol; DMBA, dimethylbenz[a]anthracene; MNU, N-methylnitrosourea; E2, 17β-estradiol; PRL, prolactin; RIA, radioanimals reached 45 days of age. A population of untreated (n ϭ 11) ovariectomized females served as controls. All animals were examined weekly immunoassay.
for the presence of palpable mammary cancers for the first 10 weeks following initiation of E2 treatment. Thereafter the animals were examined twice weekly.
Preparation and insertion of E2-containing implants
Silastic medical tubing (0.078 inch inner diameter, 0.125 inch outer diameter; Dow Corning, Midland, MI) was cut into 3 cm lengths. One end was sealed with Silastic Medical Adhesive (Silicone Type A; Dow Corning). After the adhesive had cured, 27.5 mg crystalline E2 (Sigma, St Louis, MO) were loaded into the implant and the open end was sealed with Silastic Medical Adhesive. Implants were allowed to cure for at least 24 h prior to surgical insertion. The back of each animal was shaved and disinfected, the skin was opened with sterile scissors, a s.c. cavity was created over the scapulae using the blunt end of the scissors, an implant was inserted into the cavity and the wound was closed with a sterile 9 mm clip. In the experiments in which ovary-intact animals were examined, the untreated control animals did not receive an implant. In the experiment in which ovariectomized animals were examined, an empty implant was inserted into each of the untreated control animals. The wound clip was removed 14 days following surgery.
Collection and processing of tissues
The animals were killed by decapitation. Trunk blood was collected, allowed Fig. 1 . 17β-Estradiol rapidly induces mammary cancers in female ACI rats. to clot at 4°C and centrifuged. The serum was collected and stored at -80°C.
Treatment of ovary-intact female ACI rats with E2 was initiated when the Pituitary glands were removed, weighed, fixed in 10% neutral buffered animals were 61-63 days of age. Thereafter the animals were regularly formalin and processed for embedding in paraffin. The location and size of examined for the presence of palpable mammary tumors. A single each mammary tumor was noted. Mammary tissues, both tumor and normal, E2-treated animal with no palpable mammary tumor became moribund, were removed, placed in Lillie's fixative for 24 h and processed for embedding apparently due to a pituitary tumor, following 168 days treatment. Each data in paraffin. Sections of each mammary tissue specimen were prepared, stained point represents the time after initiation of E2 treatment at which an animal with hematoxylin/eosin and examined by bright field microscopy.
exhibited its initial palpable mammary tumor. Filled circle, E2-treated animals; filled square, untreated control animals.
Radioimmunoassay of prolactin and 17β-estradiol
Prolactin (PRL) in trunk blood sera was quantified by double antibody radioimmunoassay (RIA) using an anti-rat PRL monoclonal antibody (Amersham) and methods outlined by the supplier. The sera were diluted untreated animal was killed at 49 weeks of age. The third where appropriate. PRL standards (Amersham) were calibrated by the supplier untreated rat remained tumor free at the age of 65 weeks; this against the NIH reference RP2 PRL standards. All samples were assayed
animal has yet to be killed. Numerous published studies in duplicate.
indicate that ovary-intact ACI rats very rarely develop mam-E2 in unextracted trunk blood sera was measured using a coated tube RIA mary cancers spontaneously (8,14-16,20,21).
(Diagnostic Products Corp., Los Angeles, CA). Prior to assay, the rat sera were diluted 1:2 in zero calibrator buffer obtained from the vendor. Standards All excised tumors were sectioned and histologically classi- Microscopic foci of intraductal carcinoma were often observed Treatment of ovary-intact ACI rats with E2 resulted in rapid development of mammary tumors. A palpable mammary tumor within these grossly normal mammary tissues. Mammary tissues from untreated, ovary-intact ACI rats were poorly (~2 mm in diameter) was first detected 99 days after initiation of E2 treatment (Figure 1 ). The median latency (n ϭ 21) to developed, relative to those from E2-treated animals, with virtually no lobuloalveolar tissue identified ( Figure 2E and F). appearance of the first palpable tumor was 143 days and 100% of the treated population displayed palpable tumors within 197
Mitotic figures were virtually absent in the mammary tissues from untreated rats. days of initiation of E2 treatment. The mean latency was 145 Ϯ 26 days (n ϭ 20 animals). A single E2-treated Pituitary tumors were observed in 100% of the E2-treated, ovary-intact animals. The average length of E2 treatment in animal became moribund, apparently due to a pituitary tumor, following 168 days treatment. Although no palpable mammary this population of animals was 174 Ϯ 28 days. Average pituitary wet weight was increased 6-fold (P ഛ 0.05) relative tumor was detected at the time this animal was killed, microscopic intraductal carcinoma was revealed upon histological to that observed in untreated, ovary-intact animals ( Figure  3A ). These pituitary tumors produced and released large examination of mammary tissues from this animal (data not shown). Each animal was killed when its largest mammary amounts of PRL, as evidenced by a 42-fold (P ഛ 0.05) increase in mean circulating PRL in the E2-treated population relative tumor reached a size of 1.0-1.5 cm in diameter. Upon necropsy all but one of the E2-treated animals were determined to to that observed in untreated animals ( Figure 3B ). Both pituitary weight and the level of circulating PRL in untreated harbor multiple macroscopic mammary tumors (mean 5.6, range 1-18 tumors/animal). These tumors appeared to be animals were within normal limits for ovary-intact female rats. The amount of E2 in trunk blood sera from untreated, ovaryrandomly distributed throughout the six pairs of mammary glands. No mammary tumors were observed in a population intact ACI rats was Ͻ50 pg/ml, the level of sensitivity of the RIA as performed in this study. The mean level of E2 in trunk of three untreated, ovary-intact ACI rats (Figure 1) . One of the untreated rats was killed following 20 weeks E2 treatment, blood sera from E2-treated, ovary-intact animals averaged 185 pg/ml (Figure 4 ). During the rat estrous cycle, circulating E2 so that mammary gland histology could be assessed at a time corresponding to the time point at which 50% of the E2-levels oscillate between~20 and 75 pg/ml, with peak levels occurring at midday on proestrus (25) . The rats in the present treated population developed mammary cancers. A second study were not evaluated for reproductive cycle. In another population of 11 ovariectomized females treated with E2 for 140 days (data not shown), an observation in stark contrast to experiment in which ovary-intact female rats received E2-containing Silastic implants identical to those used in the that observed in ovary-intact animals ( Figure 1 ). It is noted that the original purpose of this experiment was to assess, at present study, the rats exhibited vaginal cytological features indicative of persistent proestrus. a defined time point, the ability of administered E2 to promote development of PRL-producing pituitary tumors. Histological Ovariectomized ACI rats displayed reduced susceptibility to E2-induced mammary carcinoma relative to ovary-intact examination of grossly normal mammary tissues from these E2-treated, ovariectomized ACI rats revealed ductal and lobulofemales. No palpable mammary tumors were detected in a untreated, ovariectomized animals compared with that observed in untreated, ovary-intact animals.
The amount of E2 in trunk blood sera from untreated, ovariectomized ACI rats was Ͻ50 pg/ml. The mean level of E2 in trunk blood sera from treated, ovariectomized animals averaged 207 pg/ml (Figure 7 ).
Discussion
We have demonstrated that E2, administered from s.c. Silastic tubing implants, rapidly induces development of mammary carcinomas in ovary-intact ACI rats. To our knowledge, this is the first demonstration that this naturally occurring estrogen induces development of mammary cancers in this rat strain. Estrogens other than E2 have previously been demonstrated to promote development of mammary cancers in ACI rats. However, the form of estrogen and the manner in which it is administered significantly impact both tumor incidence and latency. For example, in their initial study Dunning et al. (8) demonstrated that DES administered from s.c. pellets of compressed crystalline hormone failed to promote mammary cancer development in female ACI rats, whereas this synthetic rats, the incidence of mammary cancers within the DES-treated populations ranged from 34 to 94% and the median latency to appearance of first tumor ranged from 158 to 425 days (8,10-13,15-18,26). Holtzman et al. (17, 21) demonstrated the ability of the semi-synthetic estrogen 17α-ethinylestradiol to induce development of mammary cancers in the female ACI rat. In those studies, the latency to appearance of first mammary cancer was similar to that observed in the present study and cancers developed in~85% of the treated populations (17, 21) . Estrone has also been demonstrated to induce, in a dosedependent manner, mammary cancers in female ACI rats (27) . However, the incidence of mammary cancers in estrone-treated ACI females ranged from 9 to 18% and the median latency ranged from 218 to 347 days, depending upon the dose of hormone administered (27) . Together, these studies strongly suggest that it is the estrogenic activity of these synthetic and naturally occurring compounds, not their chemical properties Fig. 4 . Level of 17β-estradiol in trunk blood sera from ovary-intact female per se, that is responsible for development of mammary ACI rats. Trunk blood sera from animals described in Figures 1-3 were cancers. Moreover, the data from the present study indicate assayed for E2 by RIA. E2 levels ഛ50 pg/ml could not be accurately that administration of E2 from s.c. Silastic implants is the measured. Each data bar represents the mean Ϯ SEM (E2-treated) or range (untreated). most effective mode of treatment identified to date for inducing development of mammary cancers in the ACI rat strain.
Also presented herein are data indicating that the ovary alveolar hyperplasia (Figure 5A and B) . However, neither intraductal carcinoma nor infiltrating ductal carcinoma were modulates susceptibility to estrogen-induced mammary cancers in the female ACI rat. Although the primary purpose of the observed histologically. Mammary tissues from untreated, ovariectomized animals displayed markedly atrophic lobuloexperiment in which ovariectomized females were treated with E2 for 20 weeks was not to assess the role of the ovary in the alveolar structures ( Figure 5C and D) .
Ovariectomized ACI rats treated with E2 for 140 days etiology of estrogen-induced mammary cancers, it is clear that the ovary-intact females were much more susceptible to the developed pituitary tumors at an incidence of 100%. Average pituitary wet weight was increased 5.3-fold (P ഛ 0.05) relative mammary cancer inducing effects of administered E2 than were the ovariectomized females; palpable tumors were observed in to that observed in untreated, ovariectomized females ( Figure  6A ), an increase comparable with that observed in ovary-intact~50% of the ovary-intact animals following 20 weeks E2 treatment, whereas no palpable tumors were observed in females ( Figure 3A) . In this experiment, circulating PRL was increased 283-fold by E2 treatment ( Figure 6B ). Although the ovariectomized females treated with E2 for 20 weeks. At this time we cannot state whether ovariectomy inhibits or simply relative induction of circulating PRL by E2 was greater in ovariectomized animals compared with ovary-intact animals, delays development of mammary cancers in E2-treated ACI rats. In the studies cited above in which mammary cancers this resulted entirely from the lower basal PRL levels in the were induced in female ACI rats with DES, hormone treatment Both incidence and tumor burden were low in that study, however, making interpretation difficult; five of 14 DESwas initiated in animals whose ages ranged from 50 days to 6 months and age had no apparent effect on tumor incidence treated animals developed a total of eight palpable cancers, whereas one of 13 animals treated with DES and progesterone or latency. Therefore, we do not believe that the 16-18 day age difference at initiation of E2 treatment, 61-63 days for developed two palpable cancers. When administered to Sprague-Dawley rats following treatment with DMBA, progesthe ovary-intact females and 45 days for the ovariectomized females, was responsible for the markedly differing results in terone enhanced mammary tumor development (30, 31) . It is interesting to note that cell proliferation in the breast tissues these two experiments. Ovariectomy essentially abolishes the ability of chemical and physical carcinogens, such as DMBA, of human females is greatest during the luteal phase of the menstrual cycle, when the levels of circulating progesterone NMU and ionizing radiation, to induce development of mammary cancers in the rat. However, treatment with exogenous are maximal (32, 33) . Therefore, the role of progesterone in estrogen-mediated mammary carcinogenesis in the female ACI estrogens essentially reverses the inhibitory effect of ovariectomy (28, 29) . We interpret these disparate observations to rat warrants further investigation. It has long and often been hypothesized that the large indicate that mammary cancers resulting in ACI rats from treatment with estrogens arise through a fundamentally differamount of PRL produced by estrogen-induced pituitary tumors plays a direct role in estrogen-mediated mammary carcinoent mechanism than do the mammary cancers that develop in rats treated with chemical and physical carcinogens.
genesis (14, 16, 34) . Data presented herein indicate that susceptibility to mammary cancer development in response to E2 The differing susceptibilities of ovary-intact and ovariectomized female ACI rats to E2-induced mammary cancers treatment was substantially diminished as a result of ovariectomy, whereas the ability of administered E2 to induce imply that an ovarian factor in addition to E2 is required for rapid development of mammary cancers in the E2-treated pituitary tumor development and ensuing hyperprolactinemia was similar in ovary-intact and ovariectomized female ACI female ACI rat. One ovarian factor that may act in this regard is progesterone. Segaloff (12) demonstrated that s.c.
rats. These data strongly suggest that estrogen-induced hyperprolactinemia is not the sole factor leading to development of implantation of progesterone pellets inhibits mammary cancer development in ovary-intact female ACI rats treated with DES. mammary cancers in the E2-treated ACI rat. Moreover, many important role of estrogens in the etiology of human breast cancer, it appears worthy to identify the gene or genes conferring susceptibility to estrogen-induced mammary cancers and to elucidate the mechanisms through which these genes and estrogens act in concert to promote development of mammary cancers. treated with estrogens, yet none of these strains are as highly
